X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4869) 4869
Book Review (592) 592
Publication (417) 417
Conference Proceeding (12) 12
Book Chapter (8) 8
Magazine Article (4) 4
Book / eBook (2) 2
Web Resource (2) 2
Dissertation (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (4632) 4632
humans (4191) 4191
oncology (2308) 2308
female (2174) 2174
docetaxel (2082) 2082
taxoids - pharmacology (1757) 1757
male (1748) 1748
pharmacology & pharmacy (1649) 1649
taxoids - administration & dosage (1575) 1575
animals (1439) 1439
chemotherapy (1401) 1401
middle aged (1321) 1321
cell line, tumor (1252) 1252
aged (1215) 1215
cancer (1162) 1162
antineoplastic agents - pharmacology (1122) 1122
paclitaxel (1113) 1113
antineoplastic combined chemotherapy protocols - therapeutic use (1071) 1071
taxoids (1004) 1004
adult (994) 994
taxoids - therapeutic use (960) 960
breast neoplasms - drug therapy (910) 910
mice (881) 881
paclitaxel - analogs & derivatives (765) 765
treatment outcome (702) 702
paclitaxel - pharmacology (603) 603
antineoplastic agents - therapeutic use (599) 599
breast cancer (577) 577
taxoids - chemistry (564) 564
drug resistance, neoplasm (558) 558
apoptosis - drug effects (555) 555
taxoids - adverse effects (537) 537
antineoplastic combined chemotherapy protocols - adverse effects (523) 523
breast neoplasms - pathology (522) 522
apoptosis (507) 507
antineoplastic agents - administration & dosage (501) 501
dose-response relationship, drug (488) 488
prostatic neoplasms - drug therapy (481) 481
antineoplastic agents, phytogenic - pharmacology (475) 475
taxoids - pharmacokinetics (474) 474
lung neoplasms - drug therapy (462) 462
antineoplastic agents (461) 461
medicine & public health (457) 457
prostate cancer (447) 447
therapy (445) 445
research (431) 431
expression (427) 427
antimitotic agents (425) 425
cell proliferation - drug effects (425) 425
analysis (417) 417
care and treatment (416) 416
pharmacology/toxicology (416) 416
taxol (406) 406
drug administration schedule (393) 393
neoplasms - drug therapy (386) 386
antineoplastic agents, phytogenic - therapeutic use (382) 382
paclitaxel - administration & dosage (381) 381
xenograft model antitumor assays (378) 378
breast-cancer (376) 376
cell survival - drug effects (370) 370
in-vitro (370) 370
mice, nude (367) 367
cisplatin (355) 355
chemistry, medicinal (354) 354
carcinoma, non-small-cell lung - drug therapy (348) 348
pharmacokinetics (344) 344
disease-free survival (338) 338
trial (338) 338
metastasis (336) 336
antineoplastic agents - chemistry (335) 335
tumors (332) 332
antineoplastic combined chemotherapy protocols - administration & dosage (330) 330
cancer research (330) 330
carcinoma (329) 329
deoxycytidine - analogs & derivatives (329) 329
aged, 80 and over (328) 328
nanoparticles (326) 326
taxanes (326) 326
neoplasm metastasis (316) 316
prostatic neoplasms - pathology (313) 313
biochemistry & molecular biology (310) 310
antineoplastic combined chemotherapy protocols - pharmacology (308) 308
paclitaxel - therapeutic use (308) 308
doxorubicin (304) 304
drug synergism (301) 301
drug therapy (294) 294
antineoplastic agents - pharmacokinetics (289) 289
tumor cells, cultured (289) 289
cisplatin - administration & dosage (283) 283
drug delivery systems (283) 283
article (269) 269
drugs (266) 266
lung neoplasms - pathology (266) 266
antineoplastic agents, phytogenic - administration & dosage (256) 256
taxotere (254) 254
cells (252) 252
health aspects (250) 250
phase-ii trial (250) 250
survival (246) 246
survival analysis (242) 242
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4727) 4727
Chinese (56) 56
Japanese (52) 52
French (22) 22
German (12) 12
Spanish (4) 4
Italian (3) 3
Polish (2) 2
Russian (2) 2
Hungarian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Molecular Cancer Therapeutics, ISSN 1535-7163, 10/2003, Volume 2, Issue 10, pp. 971 - 984
Histone deacetylase inhibitors induce hyperacetylation of the amino-terminal lysine residues of the core nucleosomal histones, which results in chromatin... 
SIGNAL-TRANSDUCTION | ACUTE-LEUKEMIA CELLS | ONCOLOGY | ACETYLATION | RESISTANCE | RECEPTOR | RAF-1 | MONOCLONAL-ANTIBODY | OVARIAN-CANCER | TAXOL-INDUCED APOPTOSIS | HSP90 FUNCTION | Chromatin - metabolism | Phosphorylation | Taxoids - pharmacology | Coloring Agents - pharmacology | Annexin A5 - pharmacology | Humans | Epothilones - pharmacology | Multienzyme Complexes - metabolism | Deoxycytidine - pharmacology | Proteasome Endopeptidase Complex | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized | Sepharose - pharmacology | Cysteine Endopeptidases - metabolism | Flow Cytometry | Cyclins - metabolism | Time Factors | Antimetabolites, Antineoplastic - pharmacology | Antineoplastic Agents - pharmacology | Hydroxamic Acids - pharmacology | Detergents - pharmacology | Receptor, ErbB-2 - biosynthesis | Cyclin-Dependent Kinase Inhibitor p21 | Antibodies, Monoclonal - pharmacology | Down-Regulation | Enzyme Inhibitors - pharmacology | Tetrazolium Salts - pharmacology | Reverse Transcriptase Polymerase Chain Reaction | Breast Neoplasms - drug therapy | Blotting, Western | Precipitin Tests | Blotting, Northern | Cell Line, Tumor | Histone Deacetylase Inhibitors | Thiazoles - pharmacology | Antineoplastic Agents, Phytogenic - pharmacology | Deoxycytidine - analogs & derivatives | Microscopy, Fluorescence | Trastuzumab | Apoptosis | Index Medicus
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 05/2004, Volume 96, Issue 10, pp. 739 - 749
Background. Trastuzumab, a humanized anti-HER2 antibody, increases the clinical benefit of first-line chemotherapy in patients with metastatic breast cancers... 
TUMOR-CELL LINES | GROWTH-FACTOR RECEPTOR | PHASE-II TRIAL | IN-VITRO | PACLITAXEL TAXOL(R) | ONCOLOGY | 1ST-LINE CHEMOTHERAPY | RANDOMIZED-TRIAL | MONOCLONAL-ANTIBODY | CLINICAL PHARMACOKINETICS | DOCETAXEL TAXOTERE(R) | Up-Regulation | Cyclophosphamide - analogs & derivatives | Paclitaxel - pharmacology | Taxoids - pharmacology | Neoplastic Stem Cells - drug effects | Humans | Receptor, ErbB-2 - metabolism | Deoxycytidine - pharmacology | Transplantation, Heterologous | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Breast Neoplasms - metabolism | Antibodies, Monoclonal, Humanized | Vinblastine - analogs & derivatives | Female | Gene Expression Regulation, Neoplastic - drug effects | Receptor, ErbB-2 - drug effects | Disease Models, Animal | Floxuridine - pharmacology | Cell Survival - drug effects | Tumor Stem Cell Assay | Proto-Oncogene Proteins - drug effects | Enzyme-Linked Immunosorbent Assay | Antibodies, Monoclonal - pharmacology | Docetaxel | Breast Neoplasms - drug therapy | DNA, Neoplasm - drug effects | Guanine Nucleotide Exchange Factors | Drug Synergism | Animals | Mice, Nude | Cyclophosphamide - pharmacology | Cell Line, Tumor | Mice | Vinblastine - pharmacology | Carboplatin - pharmacology | Deoxycytidine - analogs & derivatives | Doxorubicin - pharmacology | Trastuzumab | Vinorelbine | Epirubicin - pharmacology | Chemotherapy | Care and treatment | Breast cancer | Research | Health aspects | Drug therapy | Medical treatment | Index Medicus
Journal Article
Science, ISSN 0036-8075, 2/2013, Volume 339, Issue 6119, pp. 587 - 590
Journal Article
International Journal of Pharmaceutics, ISSN 0378-5173, 12/2011, Volume 421, Issue 2, pp. 332 - 340
Journal Article
Acta Biomaterialia, ISSN 1742-7061, 01/2016, Volume 30, pp. 144 - 154
imaging and biodistribution analysis of nude mice bearing HepG2 tumors after tail vein injection of free IR-780, or IR-780 loaded TPGS-PLA/NPs or... 
Liver targeting | Dopamine polymerization | Surface modification | Cancer nanotechnology | Galactosylated nanoparticles | Taxoids - pharmacology | Nanoparticles - chemistry | Humans | Vitamin E - analogs & derivatives | Polyethylene Glycols - chemistry | Lactic Acid - pharmacokinetics | Liver Neoplasms, Experimental - metabolism | Carcinoma, Hepatocellular - drug therapy | Polyesters | Indoles - pharmacology | Vitamin E - chemistry | Lactic Acid - pharmacology | Liver Neoplasms, Experimental - pathology | Polyethylene Glycols - pharmacology | Taxoids - chemistry | Lactic Acid - chemistry | Vitamin E - pharmacokinetics | Polyethylene Glycols - pharmacokinetics | Hep G2 Cells | Taxoids - pharmacokinetics | Xenograft Model Antitumor Assays | Animals | Liver Neoplasms, Experimental - drug therapy | Mice, Nude | Carcinoma, Hepatocellular - pathology | Polymers - pharmacokinetics | Polymers - pharmacology | Indoles - pharmacokinetics | Polymers - chemistry | Mice | Drug Delivery Systems - methods | Indoles - chemistry | Carcinoma, Hepatocellular - metabolism | Vitamin E - pharmacology | Drugs | Liver cancer | Drug delivery systems | Docetaxel | Vehicles | Nanoparticles | Polyethylene glycol | Tocopherols | Polymerization | Polyols | Nanotechnology | Index Medicus | Surgical implants | Biomedical materials | In vivo testing | Liver | In vivo tests | Palladium | Tumors | Cancer
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 04/2014, Volume 20, Issue 8, pp. 2104 - 2114
Purpose: When evaluated in patients with ovarian and other cancer, vintafolide (EC145), a potent folate-targeted vinca alkaloid conjugate, displayed a toxicity... 
OVEREXPRESSION | ONCOLOGY | FOLATE RECEPTOR EXPRESSION | PHASE-II | CONJUGATE | TISSUES | INHIBITORS | ANTITUMOR-ACTIVITY | CELL-LINES | CANCER | EPITHELIAL OVARIAN-CARCINOMA | Folic Acid - pharmacology | Paclitaxel - pharmacology | Taxoids - pharmacology | Humans | Antineoplastic Agents - administration & dosage | Folic Acid - administration & dosage | Cisplatin - administration & dosage | Dose-Response Relationship, Drug | Neoplasms, Experimental - pathology | Vinca Alkaloids - administration & dosage | Vinca Alkaloids - pharmacology | Camptothecin - administration & dosage | Mice, Inbred DBA | Antineoplastic Agents - pharmacology | Paclitaxel - administration & dosage | Camptothecin - analogs & derivatives | Doxorubicin - administration & dosage | Folic Acid - analogs & derivatives | Topotecan - pharmacology | Carboplatin - administration & dosage | Treatment Outcome | Cisplatin - pharmacology | Neoplasms - drug therapy | Drug Synergism | Xenograft Model Antitumor Assays | Taxoids - administration & dosage | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice, Nude | Cell Line, Tumor | Topotecan - administration & dosage | Cell Proliferation - drug effects | Mice, Inbred BALB C | HeLa Cells | Carboplatin - pharmacology | Neoplasms - pathology | Camptothecin - pharmacology | Neoplasms, Experimental - drug therapy | Doxorubicin - pharmacology | Index Medicus
Journal Article
Cell Reports, ISSN 2211-1247, 05/2017, Volume 19, Issue 8, pp. 1669 - 1684
Although non-small cell lung cancer (NSCLC) patients benefit from standard taxane-platin chemotherapy, many relapse, developing drug resistance. We established... 
lung cancer | histone methylation | taxane-platin chemotherapy | JIB-04 | GSK-J4 | KDM | histone demethylases | demethylase inhibitors | Jumonji demethylases | drug resistance | CELLS | MELANOMA | THERAPY | CHEMOTHERAPY REGIMENS | MECHANISM | GENE-EXPRESSION | LEUKEMIA | MULTIDRUG-RESISTANCE | CELL BIOLOGY | Lung Neoplasms - drug therapy | Transcription, Genetic - drug effects | Taxoids - pharmacology | Benzazepines - adverse effects | Humans | Aminopyridines - adverse effects | Lung Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Gene Expression Profiling | Taxoids - therapeutic use | Hydrazones - adverse effects | Aminopyridines - therapeutic use | Carboplatin - therapeutic use | Hydrazones - therapeutic use | Jumonji Domain-Containing Histone Demethylases - antagonists & inhibitors | Bridged-Ring Compounds - pharmacology | Neoadjuvant Therapy | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Bridged-Ring Compounds - therapeutic use | Carcinoma, Non-Small-Cell Lung - genetics | Enzyme Inhibitors - pharmacology | Benzazepines - pharmacology | Pyrimidines - pharmacology | Enzyme Inhibitors - therapeutic use | Hydrazones - pharmacology | Disease-Free Survival | Drug Resistance, Neoplasm - genetics | Animals | Benzazepines - therapeutic use | Pyrimidines - therapeutic use | Aminopyridines - pharmacology | Pyrimidines - adverse effects | Cell Line, Tumor | Mice | Carcinoma, Non-Small-Cell Lung - drug therapy | Histones - metabolism | Carboplatin - pharmacology | Methylation | Jumonji Domain-Containing Histone Demethylases - metabolism | Drug Resistance, Neoplasm - drug effects | Index Medicus
Journal Article
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 01/2013, Volume 168, Issue 1, pp. 79 - 102
BACKGROUND AND PURPOSE Cannabinoid receptor activation induces prostate carcinoma cell (PCC) apoptosis, but cannabinoids other than ?9-tetrahydrocannabinol... 
TRP channel | apoptosis | androgen | prostate | cannabinoid | ROS | ACTIVATION | HUMAN BREAST | CANNABIDIOL | ENDOCANNABINOID SYSTEM | PC-3 CELLS | CHANNEL | PHARMACOLOGY & PHARMACY | RECEPTOR POTENTIAL VANILLOID-1 | TUMOR-GROWTH | EXPRESSION | CANCER CELL-LINES | Prostatic Neoplasms - metabolism | Reactive Oxygen Species - metabolism | Taxoids - pharmacology | Nitriles - pharmacology | Apoptosis - drug effects | Humans | Receptors, Androgen - metabolism | Caspase 3 - metabolism | Cell Survival - genetics | Apoptosis - genetics | Male | Prostate - metabolism | Tosyl Compounds - pharmacology | Prostate - pathology | Drug Interactions | Receptors, Androgen - drug effects | Caspase 3 - drug effects | Tumor Cells, Cultured | Dronabinol - pharmacology | Prostatic Neoplasms - drug therapy | Cell Survival - drug effects | Prostatic Neoplasms - pathology | Androgen Antagonists - pharmacology | Cannabidiol - pharmacology | Down-Regulation - drug effects | Cannabinoids - pharmacology | Animals | TRPM Cation Channels - antagonists & inhibitors | Mice, Nude | Transient Receptor Potential Channels - drug effects | Anilides - pharmacology | Mice | Cell Cycle - drug effects | Enzymes | Starvation | Carcinoma | Growth | Genes | Fluorescence | Gene expression | Estradiol | Cannabinoids | Anopheles | Messenger RNA | DNA | Phenols | Marijuana | Tumor proteins | Prostate cancer | Cancer | Index Medicus | Research Papers with Commentaries
Journal Article
Oncotarget, ISSN 1949-2553, 2014, Volume 5, Issue 22, pp. 11399 - 11412
Docetaxel (DTX) is a useful chemotherapeutic drug for the treatment of hormone-refractory prostate cancer. However, emergence of DTX resistance has been a... 
Bcl-2 | Bcl-xL | Prostate cancer | Docetaxel | Apoptosis | Index Medicus
Journal Article